Coverage
-
March 26, 2013
A Maryland federal judge on Tuesday dismissed a consolidated securities class action accusing Human Genome Sciences Inc. and GlaxoSmithKline PLC of concealing suicide risks associated with lupus drug Benlysta, saying the plaintiffs had failed to show the companies purposefully hid reported suicides from investors.
1 other articles on this case.
View all »